{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:52:11Z","timestamp":1787017931335,"version":"build-2736575974"},"reference-count":20,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroendocrinology"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Background:<\/i><\/b> Retrospective studies are conflicting but most of them report that an increase in plasma chromogranin A (CgA) predicts tumor progression in neuroendocrine tumor (NET) patients. Prospectively, we investigated if a change in plasma CgA is associated with tumor burden changes in NET patients with disseminated disease. <b><i>Methods:<\/i><\/b> We included 239 patients treated at 5 NET centers from December 2010 to December 2013. CgA was measured within 6 weeks of a CT or MRI in a patient undergoing at least 2 scan examinations performed over a period of 1\u201324 months. In a post hoc analysis, CgA measured 3\u20136 months prior to the CT\/MRI was analyzed. Changes in tumor size were evaluated by RECIST1.1. A 25% change in CgA was chosen to discriminate between increased, decreased, or unchanged levels. <b><i>Results:<\/i><\/b> In 671 events (2 CT\/MRI scans and 2 corresponding CgA measurements), we found a weak positive correlation between the RECIST 1.1 responses and change in plasma CgA from baseline (Spearman\u2019s rank correlation coefficient: 0.15; <i>p<\/i> &#x3c; 0.05). Of 304 events in the post hoc analysis, 58 showed progression, 228 showed stable disease, and 18 showed regression, with a median change in CgA of 19% (IQR: 57 to \u201320%), \u201312% (23 to \u201338%), and \u201373% (\u201355 to \u201383%), respectively. The correlation coefficient for all sites was 0.17 (<i>p<\/i> = 0.003), and it was 0.16 (<i>p<\/i> = 0.07), 0.18 (<i>p<\/i> = 0.04), and 0.20 (<i>p<\/i> = 0.21) for small-intestinal (<i>n<\/i> = 137), pancreatic (<i>n<\/i> = 123), and unknown primary NET (<i>n<\/i> = 40), respectively. In the 58 patients showing tumor progression, the sensitivity and specificity of an increased CgA concentration were 36 and 82%, respectively, with positive and negative predictive values of 32 and 85%. <b><i>Conclusions:<\/i><\/b> In this prospective study of gastroenteropancreatic NET patients, we observed only a weak association between a change in plasma CgA and changes in tumor burden. CgA as a single biomarker was thus inadequate to predict tumor progression.<\/jats:p>","DOI":"10.1159\/000503833","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T17:00:34Z","timestamp":1570035634000},"page":"217-224","source":"Crossref","is-referenced-by-count":37,"title":["Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors"],"prefix":"10.1159","volume":"110","author":[{"given":"Gitte","family":"Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-7910","authenticated-orcid":false,"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halfdan","family":"Sorbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Thiis\u00a0Evensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Paulsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyveke","family":"Ebbesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Knigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tiensuu\u00a0Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/400_2009_26"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.941999"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000051853"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008215730767"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0001"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02030.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0666"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2012.654511"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0269"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000225952"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000500202"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.733953"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.005"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2792"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0393"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9884-3"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0043"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2428"}],"container-title":["Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/503833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/503833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:04:24Z","timestamp":1745409864000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000503833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":20,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000503833","archive":["Portico"],"relation":{},"ISSN":["0028-3835","1423-0194"],"issn-type":[{"value":"0028-3835","type":"print"},{"value":"1423-0194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]}}}